



EXPRESS MAIL NO.: EV 058 486 334 US

**RECEIVED**

AUG - 7 2003

TECH CENTER 1600/2900

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Kensil

Confirmation No.: 7453

Application No.: 09/369,941

Group Art Unit: 1632

Filed: August 6, 1999

Examiner: M. Wilson

For: COMPOSITIONS OF CPG AND SAPONIN  
ADJUVANTS AND USES THEREOF

Attorney Docket No.: 8449-156-999

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §1.56 AND §1.97**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. § 1.56 and §1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby direct the Examiner's attention to the references B01-B06 and C01-C05 listed on the attached form PTO-1449 entitled "List of References Cited by Applicant". Copies of references B01-B06 and C01-C05 are submitted herewith.


Identification of the listed references is not to be construed an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.


Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Submission of this Supplemental Information Disclosure Statement is after the mailing date of the first Office Action on the merits; therefore, pursuant to 37 C.F.R. § 1.97(c), an estimated fee of \$180.00 is due for the filing of this Disclosure Statement. Please charge the required fee, including any deficiencies in the amount estimated to be due, to Pennie & Edmonds LLP Deposit Account No. 16-1150. A duplicate of this sheet is enclosed for accounting purposes.

Date: July 31, 2003

Respectfully submitted,

 32,605  
Adriane M. Antler (Reg. No.)  
**PENNIE & EDMONDS** LLP  
1155 Avenue of the Americas  
New York, New York 10036-2711  
Phone: (212) 790-9090



LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO. 8449-156-999	APPLICATION NO 09/369,941
	APPLICANT Kensil	
	FILING DATE August 6, 1999	GROUP 1632

RECEIVED

AUG - 7 2003

TECH CENTER 1600/2900

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
B01	WO 98/40100	9/17/98	PCT				
B02	WO 98/55495	12/10/98	PCT				
B03	WO 99/58118	11/18/99	PCT				
B04	WO 99/61056	12/2/99	PCT				
B05	WO 99/62923	12/9/99	PCT				
B06	WO 00/21556	4/20/00	PCT				

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

C01	Hemmi et al., 2000, "A Toll-like receptor recognizes bacterial DNA," <i>Nature</i> 408:740-5
C02	Liu et al., 2002, "QS-21 structure/function studies: effect of acylation on adjuvant activity," <i>Vaccine</i> 20:2808-15
C03	Soltysik et al., 1995, "Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function," <i>Vaccine</i> 13:1404-10
C04	Wagner, 2001, "Toll meets bacterial CpG-DNA," <i>Immunity</i> 14:499-502
C05	Bomford et al., 1992, "Adjuvanticity and ISCOM formation by structurally diverse saponins," <i>Vaccine</i> 10:572-577

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.